about
Atypical hemolytic uremic syndromeHemolytic uremic syndrome: new developments in pathogenesis and treatmentShiga toxin 2 targets the murine renal collecting duct epitheliumComplement regulation: physiology and disease relevanceAdvances and challenges in the management of complement-mediated thrombotic microangiopathiesHemolytic uremic syndromeAtypical hemolytic-uremic syndrome: a case report and literature reviewKidney and urinary tract involvement in kawasaki diseaseClade 8 and Clade 6 Strains of Escherichia coli O157:H7 from Cattle in Argentina have Hypervirulent-Like PhenotypesProduction of biologically active recombinant human factor H in PhyscomitrellaShiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulenceRenal complications of seasonal and pandemic influenza A virus infections.Complement factor h gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid geneHemolytic uremic syndrome associated with Entamoeba histolytica intestinal infection.Haemolytic uraemic syndrome: an overview.Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndromeRecurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndromeInteractions between Shiga toxins and human polymorphonuclear leukocytes.Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.Thrombomodulin mutations in atypical hemolytic-uremic syndrome.Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration.Atypical hemolytic uremic syndrome in the Tunisian population.Genetics and complement in atypical HUS.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP.Clinical aspects of a nationwide epidemic of severe haemolytic uremic syndrome (HUS) in children.Common variable immunodeficiency complicated with hemolytic uremic syndromeIndicators of acute and persistent renal damage in adult thrombotic microangiopathy.Clinical grand rounds: atypical hemolytic uremic syndrome.Endothelial cells and thrombotic microangiopathy.Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding.Thrombotic microangiopathy and associated renal disorders.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.
P2860
Q21202864-A35B2727-B33A-42FE-B1D3-DA57D63DC2F9Q24613517-608DE068-9D68-4D11-A1DE-4A59A34A6BDBQ24652310-CB67CB21-09DA-4D6D-ACB5-F29EC9DBDBA2Q26795441-EC3E7C69-BA20-478F-B2BD-458BED0A0CA4Q26796453-66C3072A-C325-4444-880F-B725E540214DQ26799054-63C44259-B3EE-46EE-9C51-55F443064D0EQ27003863-6E7D259C-93E5-4D67-A0A1-AC3C4D81A72FQ27009431-7E26C65E-4174-4395-89F3-37B1612AAFB1Q27306436-400B3280-C72E-4ACB-8184-413ABF222877Q28290970-B1DB4EB0-54E6-4ECD-BBDF-34A3FFED671DQ30411012-C810623A-6DC7-4836-B388-5AF6B727DCEAQ30422342-46504531-A15F-4653-8185-75D484572B1BQ33262235-0E583583-11F9-4C20-A6C4-3633A04010B1Q33368907-205426D9-5C80-4E44-8B1A-596987A6DFF6Q33371444-C7CA6328-F819-49C2-9870-8999B33D8668Q33372382-FB47C073-F1E5-40DA-AD5D-1D541B9E82D4Q33372897-E162D2E3-F4ED-48A4-BC5A-40D38856D27FQ33375818-D569E624-DB29-4763-82C4-8595947E96AAQ33377727-339320ED-D18C-4834-8180-C4B364ADFC16Q33377799-C0199F03-8C67-4FF4-9E98-D9747AC00E11Q33378469-B390E29E-5827-46E5-B69E-7E5141AD23F3Q33380350-8EE739D7-2BE7-4A3B-A2E6-9EF3B5EE1E11Q33381980-05440257-420E-43F9-B18F-F9222D66C10FQ33382404-74A06C76-55B7-4B2C-BC06-8B0A5BF29643Q33385035-2ADA341F-E7B6-4748-ADB8-C442FEC3E6E0Q33385154-2FD93044-6596-4688-ACFF-95A10FE7CB6CQ33385474-A813B188-6BB2-4A32-AD69-5C46467A169AQ33389052-CCAF696C-67A7-4FC5-8831-2693AEBB4319Q33389773-B12D9C89-C80D-430D-84D9-6E845F97288FQ33389945-F8D730C3-FC1C-4242-8DD3-BBAFBE5BB2E0Q33395774-F54D9D9C-5E9B-4B56-9B9F-275B13570EFBQ33395944-9799C06B-3108-4301-990C-466B97126BEEQ33396410-4B6A9742-28C8-4ABB-9391-606CC523B280Q33398023-F2B3F626-C02E-434A-A7AA-1B19EB9D7292Q33399411-A3C58313-F215-40AD-9A4C-50BF64BF2FEAQ33400834-7B4F68E0-A22D-4125-85C1-04726173C50BQ33401369-0A3DF0AF-605C-4586-9DA9-D712445AF1E4Q33401619-16503DEB-127C-470F-9941-681DFAC111FEQ33402372-C9FC0F16-6602-4D38-B4CE-F31BE1B461DFQ33402784-B4880C43-8195-4563-BFC2-3177A7EACABD
P2860
description
scientific article published on 23 February 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2005
@uk
name
Hemolytic Uremic Syndrome
@en
Hemolytic Uremic Syndrome
@nl
type
label
Hemolytic Uremic Syndrome
@en
Hemolytic Uremic Syndrome
@nl
prefLabel
Hemolytic Uremic Syndrome
@en
Hemolytic Uremic Syndrome
@nl
P356
P1476
Hemolytic uremic syndrome
@en
P2093
Marina Noris
P304
P356
10.1681/ASN.2004100861
P577
2005-02-23T00:00:00Z